CNBCLean R·
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Read at CNBC →
Business · 1 sources covering this
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/1cb80ada3344d8b25083b3167fc523ae558e7cd7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC"></iframe>
